地塞米松用于心脏手术:实践偏好随机知情同意的比较效果试验
这项在澳大利亚和荷兰七家医院开展的实用性国际试验,采用预先随机知情同意设计,将1951例心脏手术患者随机分配至地塞米松1 mg/kg组或不使用地塞米松组。结果显示,地塞米松未增加术后30天内居家天数(中位差0.1天,95%CI -0.3至0.5,P=0.66),但缩短了ICU停留时间(中位29小时 vs 43小时,P=0.004)。
要点
- 地塞米松1 mg/kg未增加心脏手术后30天内居家天数。
- 地塞米松缩短了ICU停留时间,中位29小时对比43小时。
- 两组在延长机械通气、脓毒症、肾衰竭、心梗、卒中和死亡方面无显著差异。
核心结论
- 心脏手术患者使用高剂量地塞米松未增加术后居家天数,但缩短了ICU停留时间。
研究设计与样本
- 实用性国际试验,采用预先随机知情同意设计,在澳大利亚和荷兰七家医院纳入1951例心脏手术患者,随机分配至地塞米松1 mg/kg组或不使用地塞米松组。
主要发现
- 地塞米松组与对照组的中位居家天数分别为23.1天(IQR 20.1至24.6)和23.0天(IQR 20.1至24.1),中位差0.1天(95%CI -0.3至0.5,P=0.66)。
- 地塞米松组ICU停留时间中位29小时(IQR 22至50),对照组中位43小时(IQR 24至72),P=0.004。
- 延长机械通气风险比0.72(95%CI 0.48至1.08),脓毒症风险比1.02(95%CI 0.57至1.82),肾衰竭风险比0.94(95%CI 0.80至1.12),心肌梗死风险比1.20(95%CI 0.30至4.82),卒中风险比1.06(95%CI 0.54至2.08),死亡风险比0.72(95%CI 0.22至2.35),所有P>0.10。
- 试验设计入组效率高,入组率为89.3%。
临床怎么用
- 对于心脏手术患者,地塞米松1 mg/kg可考虑用于缩短ICU停留时间,但不应期望增加术后居家天数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-dose corticosteroids have been used to attenuate the inflammatory response to cardiac surgery and cardiopulmonary bypass, but patient outcome benefits remain unclear. The primary aim was to determine whether using dexamethasone was superior to not using dexamethasone to increase the number of home days in the first 30 days after cardiac surgery. The secondary aim was to evaluate efficiency, value, and impact of the novel trial design. METHODS: This pragmatic, international trial incorporating a prerandomized consent design favoring local practice enrolled patients undergoing cardiac surgery across seven hospitals in Australia and The Netherlands. Patients were randomly assigned to dexamethasone 1 mg/kg or not (control). The primary outcome was the number of days alive and at home up to 30 days after surgery ("home days"). Secondary outcomes included prolonged mechanical ventilation (more than 48 h), sepsis, renal failure, myocardial infarction, stroke, and death. RESULTS: Of 2,562 patients assessed for eligibility, 1,951 were randomized (median age, 63 yr; 80% male). The median number of home days was 23.0 (interquartile range, 20.1 to 24.1) in the no dexamethasone group and 23.1 (interquartile range, 20.1 to 24.6) in the dexamethasone group (median difference, 0.1; 95% CI, -0.3 to 0.5; P = 0.66). The rates of prolonged mechanical ventilation (risk ratio, 0.72; 95% CI, 0.48 to 1.08), sepsis (risk ratio, 1.02; 95% CI, 0.57 to 1.82), renal failure (risk ratio, 0.94; 95% CI, 0.80 to 1.12), myocardial infarction (risk ratio, 1.20; 95% CI, 0.30 to 4.82), stroke (risk ratio, 1.06; 95% CI, 0.54 to 2.08), and death (risk ratio, 0.72; 95% CI, 0.22 to 2.35) were comparable between groups (all P > 0.10). Dexamethasone reduced intensive care unit stay (median, 29 h; interquartile range, 22 to 50 h vs. median, 43 h; interquartile range, 24 to 72 h; P = 0.004). The authors' novel trial design was highly efficient (89.3% enrollment). CONCLUSIONS: Among patients undergoing cardiac surgery, high-dose dexamethasone decreased intensive care unit stay but did not increase the number of home days after surgery.
引用
- Myles PS, Dieleman JM, Munting KE, et al. Dexamethasone for Cardiac Surgery: A Practice Preference-Randomized Consent Comparative Effectiveness Trial. Anesthesiology. 2024. PMID: 38904693. doi:10.1097/ALN.0000000000005127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。